Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?

Laika, B.; Leucht, S.; Heres, S.; Steimer, W.
December 2009
Pharmacogenomics Journal;Dec2009, Vol. 9 Issue 6, p395
Academic Journal
The cytochrome P450 2D6 (CYP2D6) isoenzyme metabolizes about 25% of clinically used drugs. The impact of CYP2D6 metabolizer status on therapeutic outcome was assessed in 365 psychiatric in-patients treated with neuroleptics or antidepressants. Length of hospitalization and response onset were prolonged for patients receiving CYP2D6 drugs. Intermediate metabolizers (IMs) receiving CYP2D6 doses above the population median had more side effects after 4 weeks than extensive metabolizers with above-median doses (9/13, 69% vs 4/23, 17%, P=0.003), than IMs with below-median doses (5/22, 23%, P=0.012) and IMs with other medication (24/84, 29%, P=0.009). The Clinical Global Impression scale response was lower for IMs treated with CYP2D6 drugs (3/42, 7%) than for IMs with other medication (21/84, 25%, P=0.017) probably due to increased side effects. Identification of IM status (38% of study population) may help to reduce side effects and length/cost of hospitalization. Thus, not only poor and ultrarapid metabolizer but also IMs may benefit from CYP2D6 genotyping. This is of paramount interest since it greatly improves cost/benefit estimations for pretreatment CYP2D6 screening.


Related Articles

  • Fatal intoxication cases: cytochromeP 4502D6 and 2C19 genotype distributions. Zackrisson, A.L.; Holmgren, P.; Gladh, A.B.; Ahlner, J.; Lindblom, B. // European Journal of Clinical Pharmacology;Oct2004, Vol. 60 Issue 8, p547 

    Objective: Many commonly used pharmaceuticals, such as antidepressants and neuroleptics as well as some illegal drugs, are metabolised by the cytochrome P 450 enzyme debrisoquine 4-hydroxylase (CYP2D6). Of Caucasians, 7-10% lack this enzyme, which can, upon administration of drugs in normal...

  • Pharmacogenetics of Antipsychotics. Brandl, Eva J.; Kennedy, James L.; Müller, Daniel J. // Canadian Journal of Psychiatry;Feb2014, Vol. 59 Issue 2, p76 

    Objective: During the past decades, increasing efforts have been invested in studies to unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response, and occurrence of adverse effects. These studies aimed to improve clinical care by predicting outcome of treatment...

  • Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. Gurwitz, D.; Lunshof, J. E.; Dedoussis, G.; Flordellis, C. S.; Fuhr, U.; Kirchheiner, J.; Licinio, J.; Llerena, A.; Manolopoulos, V. G.; Sheffield, L. J.; Siest, G.; Torricelli, F.; Vasiliou, V.; Wong, S. // Pharmacogenomics Journal;2005, Vol. 5 Issue 4, p221 

    Pharmacogenomics would be instrumental for the realization of personalized medicine in coming decades. Efforts are evident to clarify the potential bioethical, societal, and legal implications of key pharmacogenomics-based technologies projected to be soon introduced into the core practice of...

  • Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Pilgrim, J. L.; Gerostamoulos, D.; Drummer, Olaf H. // Forensic Science, Medicine & Pathology;Jun2011, Vol. 7 Issue 2, p162 

    The field of pharmacogenetics contains a wealth of potential for the enhancement of clinical practice by providing a more effective match between patient and drug, consequently reducing the probability of an adverse drug reaction. Although a relatively novel concept in the forensic context,...

  • El apoyo del citocromo P450 (CYP2D6) en el uso de medicamentos antipsicóticos. Flores-Pérez, Janett; Cruz-Reyes, Irma A.; Flores-Pérez, Carmen // Acta Pediatrica de Mexico;nov/dic2007, Vol. 28 Issue 6, p278 

    Metabolic polymorphism can alter the efficiency of a treatment or influence the occurrence of adverse reactions. Cytochrome 450, includes CYP2D6 which metabolizes 20% of drugs such as antipsychotic and antidepressive. Several studies have shown significant racial differences in the prevalence of...

  • Drug interactions that matter. Brewer, Linda; Williams, David // Africa Health;Mar2013, Vol. 35 Issue 3, p36 

    Drug-drug interactions arise when the effects of one drug are altered by the co-administration of another. The clinical response seen depends on many factors, including individual patient characteristics such as age, co-morbidities and pharmacogenetics. The number of potential drug interactions...

  • Pharmacogenomics- The Promise of Personalized Medicine. Fakruddin, M.; Chowdhury, A. // Bangladesh Journal of Medical Science;Oct2013, Vol. 12 Issue 4, p346 

    Introduction: Pharmacogenomics (PGx) is the study of the genetic basis of variability among individuals in response to drugs. It is the newest discipline of medicine and is becoming a very active area of research, with the pharmaceutical industry gaining experience applying it, integrating it...

  • Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Hawcutt, D B; Ghani, A A; Sutton, L; Jorgensen, A; Zhang, E; Murray, M; Michael, H; Peart, I; Smyth, R L; Pirmohamed, M // Pharmacogenomics Journal;Dec2014, Vol. 14 Issue 6, p542 

    Warfarin is used in paediatric populations, but dosing algorithms incorporating pharmacogenetic data have not been developed for children. Previous studies have produced estimates of the effect of polymorphisms in Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1...

  • Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes. Mukonzo, Jackson K.; Owen, Joel S.; Ogwal-Okeng, Jasper; Kuteesa, Ronald B.; Nanzigu, Sarah; Sewankambo, Nelson; Thabane, Lehana; Gustafsson, Lars L.; Ross, Colin; Aklillu, Eleni // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (EFV), leading to variations in both efficacy and toxicity. The purpose of this study was to assess the effect of genetic factors on EFV pharmacokinetics, treatment outcomes and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics